Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Dyslipidemia

Free Subscription Articles published in J Am Coll Cardiol Retrieve available abstracts of 26 articles: HTML format

Single Articles

November 2025
1. LEE HH, Crawford EB, Cho SMJ, Krawisz AK, et al
   Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.
   J Am Coll Cardiol. 2025 Nov 26:S0735-1097(25)09917.
   PubMed     Abstract available
   
   
   September 2025
2. BLAIS JE, Yan VKC, Chan EWY, Wong ICK, et al
   Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.
   J Am Coll Cardiol. 2025;86:797-809.
   PubMed     Abstract available
   
   
   
3. AMBROSY AP, Daida YG, Parikh RV, Tan TC, et al
   Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations.
   J Am Coll Cardiol. 2025;86:725-734.
   PubMed     Abstract available
   
   
   August 2025
4. NICHOLLS SJ, Nelson AJ, Ray KK, Ballantyne CM, et al
   Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.
   J Am Coll Cardiol. 2025 Aug 20:S0735-1097(25)07383.
   PubMed     Abstract available
   
   
   June 2025
5. KOREN MJ, Vega RB, Agrawal N, Xu Y, et al
   An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial.
   J Am Coll Cardiol. 2025;85:1996-2007.
   PubMed     Abstract available
   
   
   May 2025
6. NORDESTGAARD AT, Tybjaerg-Hansen A, Mansbach H, Kersten S, et al
   Target Populations for Novel Triglyceride-Lowering Therapies.
   J Am Coll Cardiol. 2025;85:1876-1897.
   PubMed     Abstract available
   
   
   
7. XIE X, Shi X, Zhang Y, Su S, et al
   Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.
   J Am Coll Cardiol. 2025;85:1821-1835.
   PubMed     Abstract available
   
   
   
8. RAY KK, Linnebjerg H, Michael LF, Shen X, et al
   Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies.
   J Am Coll Cardiol. 2025;85:1803-1818.
   PubMed     Abstract available
   
   
   
9. BALLANTYNE CM, Gaudet D, Rosenson RS, Hegele RA, et al
   Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia.
   J Am Coll Cardiol. 2025;85:1839-1854.
   PubMed     Abstract available
   
   
   November 2024
10. SUN Y, Lv Q, Guo Y, Wang Z, et al
    Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial.
    J Am Coll Cardiol. 2024;84:2037-2047.
    PubMed     Abstract available
    
    
    
11. XU M, Wang Z, Zhang Y, Liu Y, et al
    Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial.
    J Am Coll Cardiol. 2024;84:2026-2036.
    PubMed     Abstract available
    
    
    September 2024
12. TOTH PP
    Triglycerides and Cardiovascular Risk: Getting to the Heart of the Matter.
    J Am Coll Cardiol. 2024;84:1007-1009.
    PubMed    
    
    
    April 2024
13. WRIGHT RS, Leiter LA, Lesogor A, Ray KK, et al
    Reply: Evaluation of the Inclisiran Safety in High-Risk Populations.
    J Am Coll Cardiol. 2024;83:e129.
    PubMed    
    
    
    
14. JIANG X, Zhang Z, Ding H
    Evaluation of the Inclisiran Safety in High-Risk Populations.
    J Am Coll Cardiol. 2024;83:e127.
    PubMed    
    
    
    March 2024
15. SZAREK M, Bhatt DL, Miller M, Brinton EA, et al
    Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
    J Am Coll Cardiol. 2024 Mar 15:S0735-1097(24)00384.
    PubMed     Abstract available
    
    
    
16. BLAHA MJ, Bhatia HS
    Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy.
    J Am Coll Cardiol. 2024 Mar 9:S0735-1097(24)00944.
    PubMed    
    
    
    December 2023
17. BALLANTYNE CM, Minhas AMK, Orringer CE
    Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?
    J Am Coll Cardiol. 2023;82:2262-2264.
    PubMed    
    
    
    
18. WRIGHT RS, Koenig W, Landmesser U, Leiter LA, et al
    Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials.
    J Am Coll Cardiol. 2023;82:2251-2261.
    PubMed     Abstract available
    
    
    October 2023
19. GIDDING SS
    Childhood Screening for Familial Hypercholesterolemia: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;82:1558-1563.
    PubMed     Abstract available
    
    
    August 2023
20. BEN-YEHUDA O
    Combination Therapy With Lower Statin Dose and the Race to LDL-C Goal: A Clear Winner?
    J Am Coll Cardiol. 2023;82:411-413.
    PubMed    
    
    
    
21. LEE SJ, Joo JH, Park S, Kim C, et al
    Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention.
    J Am Coll Cardiol. 2023;82:401-410.
    PubMed     Abstract available
    
    
    July 2023
22. KALRA DK, Vorla M, Michos ED, Agarwala A, et al
    Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;82:171-181.
    PubMed     Abstract available
    
    
    
23. MORALES J, Handelsman Y
    Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2023;82:161-170.
    PubMed     Abstract available
    
    
    May 2023
24. KAZI DS, DeJong C, Chen R, Wadhera RK, et al
    The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease.
    J Am Coll Cardiol. 2023;81:2103-2111.
    PubMed     Abstract available
    
    
    April 2023
25. CHOI D, Malick WA, Koenig W, Rader DJ, et al
    Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus Seminar 1/3.
    J Am Coll Cardiol. 2023;81:1621-1632.
    PubMed     Abstract available
    
    
    
26. BALLANTYNE CM, Banka P, Mendez G, Garcia R, et al
    Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
    J Am Coll Cardiol. 2023;81:1553-1564.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.